Amyotrophic lateral sclerosis market

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Mitsubishi replacing RADICAVA’s Intravenous (IV) formulation with Oral. Opinion on Amylyx Pharma’s recent approval, RELYVRIO  The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpoo...

Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. The disease progresses over 3–5 years, making voluntary movements of arms and legs impossible. I...

Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease is a progressive, rarely occurring neurological disease that mainly involves the nerve cells (neurons) which are responsible for controlling voluntary muscle movements. With time, it leads to muscle weakness, gradually affecting the functions of ...